Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in
the treatment of numerous retinal diseases, most notably exudative age-related macular …

Intravitreal antivascular endothelial growth factor (anti-VEGF) treatment has drastically
improved the visual and anatomical outcomes in patients with diabetic macular edema …

Importance The comparative clinical effectiveness of ranibizumab, aflibercept, and
bevacizumab for the management of macular edema due to central retinal vein occlusion …

Importance The determination of optical coherence tomography (OCT) central subfield
thickness (CST) is an objective measure, and visual acuity (VA) is a subjective measure …

Diabetic macular edema (DME) is the abnormal accumulation of fluid in the subretinal or
intraretinal spaces in the macula in patients with diabetic retinopathy and leads to severely …

Diabetic macular oedema (DMO) is the major cause of visual impairment in people with
diabetes. Optical coherence tomography (OCT) is now the most widely used modality to …

The prevalence of diabetes is rapidly increasing, and it is now the leading cause of
blindness worldwide. Although early detection of diabetic retinopathy is key to preventing …

Anti-vascular endothelial growth factor (VEGF) agents are widely regarded as the first line of
therapy for diabetic macular edema (DME) but are not universally effective. An automatic …

Background Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the
standard of care for diabetic macular edema (DME), a common complication of diabetes …

Refractory diabetic macular edema (DME) to monthly intravitreal anti-vascular endothelial
growth factor (VEGF) monotherapy has a prevalence of approximately 40% in landmark …